Header Logo

Connection

Sunita Nathan to Hematopoietic Stem Cell Transplantation

Back to Details
This is a "connection" page, showing publications Sunita Nathan has written about Hematopoietic Stem Cell Transplantation.
Sunita Nathan
Connection Strength
10.866
Hematopoietic Stem Cell Transplantation
  1. Significance of isolated deletion (20q) in donor cells after allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2020 08; 61(8):2008-2011.
    View in: PubMed
    Score: 0.630
  2. DLBCL After Allogeneic HCT in a Patient With Transformed DLBCL: Does It Matter Whether Relapse or PTLD? Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):264-266.
    View in: PubMed
    Score: 0.616
  3. Necessity for treatment of steroid refractory severe GIT GVHD: patience of providers. Bone Marrow Transplant. 2020 04; 55(4):833-835.
    View in: PubMed
    Score: 0.599
  4. Complications of Stem Cell Transplantation that Affect Infections in Stem Cell Transplant Recipients, with Analogies to Patients with Hematologic Malignancies. Infect Dis Clin North Am. 2019 06; 33(2):331-359.
    View in: PubMed
    Score: 0.586
  5. Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE-BMT Risk Score. J Am Heart Assoc. 2024 Jan 02; 13(1):e033599.
    View in: PubMed
    Score: 0.204
  6. Post-transplantation cyclophosphamide is associated with increased bacterial infections. Bone Marrow Transplant. 2024 Jan; 59(1):76-84.
    View in: PubMed
    Score: 0.201
  7. Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. Transplant Cell Ther. 2024 Jan; 30(1):114.e1-114.e16.
    View in: PubMed
    Score: 0.200
  8. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis. Blood Adv. 2023 08 08; 7(15):3993-4002.
    View in: PubMed
    Score: 0.198
  9. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 09; 29(9):548-555.
    View in: PubMed
    Score: 0.197
  10. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023 Jul 01; 108(7):1900-1908.
    View in: PubMed
    Score: 0.197
  11. Scedosporium infection disseminated "from toe to head" in allogeneic stem cell transplant recipient: a case report. BMC Infect Dis. 2023 May 25; 23(1):353.
    View in: PubMed
    Score: 0.195
  12. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. Am J Hematol. 2023 04; 98(4):608-619.
    View in: PubMed
    Score: 0.191
  13. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023 01 01; 108(1):150-160.
    View in: PubMed
    Score: 0.190
  14. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients. Leukemia. 2023 05; 37(5):1006-1017.
    View in: PubMed
    Score: 0.188
  15. Myeloablative TBI is associated with increased risk of pulmonary GVHD in patients undergoing allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 10; 57(10):1632-1634.
    View in: PubMed
    Score: 0.185
  16. Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. Blood Adv. 2022 07 12; 6(13):3991-3995.
    View in: PubMed
    Score: 0.184
  17. Transplantation provides superior survival high risk myeloid malignancies in older patients. Leuk Lymphoma. 2022 10; 63(10):2494-2498.
    View in: PubMed
    Score: 0.182
  18. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant. 2022 07; 57(7):1150-1163.
    View in: PubMed
    Score: 0.182
  19. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar 01; 8(3):404-411.
    View in: PubMed
    Score: 0.179
  20. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022 01 11; 6(1):339-357.
    View in: PubMed
    Score: 0.178
  21. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022 01 08; 6(3):828-847.
    View in: PubMed
    Score: 0.178
  22. Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplant Cell Ther. 2022 06; 28(6):335.e1-335.e17.
    View in: PubMed
    Score: 0.175
  23. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplant. 2022 01; 57(1):31-37.
    View in: PubMed
    Score: 0.174
  24. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. Blood Adv. 2021 09 28; 5(18):3528-3539.
    View in: PubMed
    Score: 0.174
  25. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant. 2021 12; 56(12):3068-3077.
    View in: PubMed
    Score: 0.174
  26. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2021 08 01; 106(8):2295-2296.
    View in: PubMed
    Score: 0.172
  27. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021 06 10; 137(23):3291-3305.
    View in: PubMed
    Score: 0.171
  28. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplant Cell Ther. 2021 08; 27(8):679.e1-679.e8.
    View in: PubMed
    Score: 0.169
  29. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 09; 56(9):2108-2117.
    View in: PubMed
    Score: 0.169
  30. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683.
    View in: PubMed
    Score: 0.167
  31. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplant Cell Ther. 2021 01; 27(1):68.e1-68.e9.
    View in: PubMed
    Score: 0.163
  32. COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter. Leukemia. 2020 10; 34(10):2809-2812.
    View in: PubMed
    Score: 0.161
  33. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2020 11; 26(11):2139-2146.
    View in: PubMed
    Score: 0.161
  34. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 07 14; 4(13):3180-3190.
    View in: PubMed
    Score: 0.160
  35. Tissue mast cell counts may be associated with decreased severity of gastrointestinal acute GVHD and nonrelapse mortality. Blood Adv. 2020 05 26; 4(10):2317-2324.
    View in: PubMed
    Score: 0.159
  36. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 10; 191(1):44-51.
    View in: PubMed
    Score: 0.158
  37. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020 05 12; 4(9):1965-1973.
    View in: PubMed
    Score: 0.158
  38. Biosimilar infliximab administration for the management of acute graft-versus-host disease. J Oncol Pharm Pract. 2020 Dec; 26(8):2047-2051.
    View in: PubMed
    Score: 0.158
  39. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Br J Haematol. 2020 08; 190(4):573-582.
    View in: PubMed
    Score: 0.158
  40. Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020 03 24; 4(6):983-992.
    View in: PubMed
    Score: 0.157
  41. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biol Blood Marrow Transplant. 2020 06; 26(6):1137-1143.
    View in: PubMed
    Score: 0.156
  42. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020 05 15; 126(10):2279-2287.
    View in: PubMed
    Score: 0.156
  43. Allogeneic transplantation in elderly patients =65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 12 03; 9(12):97.
    View in: PubMed
    Score: 0.154
  44. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2020 01 15; 126(2):293-303.
    View in: PubMed
    Score: 0.152
  45. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica. 2020 05; 105(5):1329-1338.
    View in: PubMed
    Score: 0.152
  46. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 06 25; 3(12):1826-1836.
    View in: PubMed
    Score: 0.149
  47. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019 05; 54(5):648-661.
    View in: PubMed
    Score: 0.146
  48. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 01 10; 12(1):6.
    View in: PubMed
    Score: 0.144
  49. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019 05; 54(5):662-673.
    View in: PubMed
    Score: 0.143
  50. Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 05; 25(5):e145-e154.
    View in: PubMed
    Score: 0.143
  51. Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):e46-e54.
    View in: PubMed
    Score: 0.143
  52. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 11 13; 2(21):2922-2936.
    View in: PubMed
    Score: 0.143
  53. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biol Blood Marrow Transplant. 2018 03; 24(3):486-493.
    View in: PubMed
    Score: 0.134
  54. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016 07; 174(2):235-48.
    View in: PubMed
    Score: 0.119
  55. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 08 15; 25(16):5143-5155.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.